Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of ABT-981 in knee osteoarthritis
2013-003467-60Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2014
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of lutikizumab in knee osteoarthritis (OA) and osteoarthritis (OA), sponsored by AbbVie Inc. Primary endpoints: Change from baseline to Week 16 in osteoarthritis knee pain and Change from baseline to Week 26 in synovitis/effusion volume of the index knee. Started May 2014; status: completed.
02
Drugs
lutikizumab
03
Conditions
knee osteoarthritis (OA)osteoarthritis (OA)
Beyond the preview
Go deeper on 2013-003467-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003467-60.